Cullinan Therapeutics, Inc. (CGEM) Stock Price & Analysis
Cullinan Therapeutics, Inc. (CGEM) fell 1.04% to USD 17.1 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
CGEM last closed at USD 17.28; the session ranged USD 17.06–17.56 on volume of 291,455 shares. Market capitalization is $1.05B, with a 52-week range of USD 5.68–19.43 (NMS). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 17.1 |
|---|---|
| Change | ▼ 1.04% (down) |
| Previous Close | USD 17.28 |
| Open | USD 17.4 |
| Day Range | USD 17.06 – 17.56 |
| 52-Week Range | USD 5.68 – 19.43 |
| Volume | 291,455 shares |
| Market Cap | $1.05B |
| Exchange | NMS |
Technical Analysis (CGEM)
Nexqual's technical model rates CGEM "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.02 (neutral) |
| vs SMA50 | Above (USD 16.12) |
| MACD | 0.36 (positive) |
Analyst Ratings (CGEM)
Wall Street analysts rate CGEM "None" based on 11 analysts, with a mean price target of USD 31.55 (range USD 24–38), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 31.55 |
| High Target | USD 38 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (CGEM)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.85 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.75 vs est -0.84 ▲ beat |
| 2025-12-31 | USD -0.77 vs est -0.84 ▲ beat |
| 2025-09-30 | USD -0.77 vs est -0.89 ▲ beat |
| 2025-06-30 | USD -1.07 vs est -0.86 ▼ miss |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (CGEM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -48.16% |
| Debt / Equity | 0.65 |
| Current Ratio | 10.28 |
| Total Cash | $351.88M |
| Total Debt | $2.38M |
| Free Cash Flow | $-102.82M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (CGEM)
Nexqual rates Cullinan Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $352M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$179M |
| Efficiency | Critical — ROE -48%, ROA -30.6% |
Ownership (CGEM)
| Insider Ownership | +0.45% |
|---|---|
| Institutional Ownership | +107.77% |
| Shares Outstanding | 61.46M |
| Float | 44.16M |
| Short % of Float | +24.47% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (CGEM)
Cullinan Therapeutics, Inc. is led by Nadim Ahmed M.S. (age 57), President, CEO & Director, per Nexqual as of July 25, 2026 at 02:21 UTC.
| President, CEO & Director | Nadim Ahmed M.S. (age 57) |
|---|---|
| Chief Financial Officer | Mary Kay Fenton (age 61) |
| Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | Patrick A. Baeuerle (age 67) |
| Chief Scientific Officer | Jennifer Michaelson (age 58) |
| Senior Vice President of Corporate Affairs | Rose Weldon |
Major Backers & Investors (CGEM)
Notable institutional backers of Cullinan Therapeutics, Inc. include Lynx1 Capital Management Lp, MPM Bioimpact LLC, BVF Inc., according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lynx1 Capital Management Lp | 14.58% |
| MPM Bioimpact LLC | 12.44% |
| BVF Inc. | 9.36% |
| Kynam Capital Management, LP | 5.07% |
| Price (T.Rowe) Associates Inc | 3.3% |
| Blue Owl Capital Holdings LP | 3.11% |
| RTW Investments LP | 2.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.62% |
| State Street | 7.99% |
| Vanguard Group | 7.99% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Cullinan Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
- It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
- The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer.
- It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
| IMCR | Immunocore Holdings plc | USD 35 | ▼ 1.52% |
| BCAB | BioAtla, Inc. | USD 3.37 | ▼ 0.59% |
| FHTX | Foghorn Therapeutics Inc. | USD 4.85 | ▼ 6.91% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.